Gabapentin
Product Images NDC 33261-051

7 FDA label images from Aidarex Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 33261-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Gabapentin Tabs Aurobindo 1)

Chemical Structure (Gabapentin Tabs Aurobindo 1)
Chemical structure of gabapentin showing a cyclohexane ring with attached amino and acetic acid groups.*
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Tabs Aurobindo 2)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Tabs Aurobindo 2)
A line graph showing mean pain scores over an 8-week period comparing placebo to Gabapentin at 3600 mg/day. The x-axis represents weeks with baseline through week 8, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin data points show a progressive decrease in pain score compared to placebo, with statistical significance indicated (p < 0.01).*
FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Tabs Aurobindo 3)

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Tabs Aurobindo 3)
Line graph depicting mean pain scores over a 7-week period comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows weeks from baseline to week 7, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with Gabapentin groups showing statistically significant lower pain scores compared to placebo at multiple points.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Tabs Aurobindo 4)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Tabs Aurobindo 4)
A bar chart comparing the percentage of responders at endpoint in two studies for Gabapentin (GBP) at doses of 1800, 2400, and 3600 mg with placebo (PBO). The y-axis represents the percentage of responders, and the chart includes statistical significance markers (p < 0.01, p < 0.001) showing higher response rates for Gabapentin at all doses compared to placebo.*
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Tabs Aurobindo 5)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Tabs Aurobindo 5)
A scatter plot comparing the percentage difference in response across three studies (a, b, c) at various daily doses of gabapentin (mg). The horizontal axis shows dose levels from 600 to 1800 mg, and the vertical axis indicates difference percentages ranging from 2% to 22%. Each study is represented by different markers and labeled accordingly.*
FDA Label Image

Image Label (Gabapentin Tabs Aurobindo 6)

Image Label (Gabapentin Tabs Aurobindo 6)
Gabapentin 600 mg film-coated tablets, 30 count, by Aidarex Pharmaceuticals LLC. The label indicates packaging and distribution by Aidarex Pharmaceuticals LLC and manufacturing by Aurobindo Pharma Limited, India. It includes directions for use with blanks for dosage and timing, and the product is identified as generic for Neurontin.*
FDA Label Image

Image Label (Gabapentin Tabs Aurobindo 7)

Image Label (Gabapentin Tabs Aurobindo 7)
Gabapentin 800 mg film-coated tablets label from Aidarex Pharmaceuticals LLC. The label indicates a package of 60 tablets, generic for Neurontin. Manufacturer listed as Aurobindo Pharma Ltd., Nagar, India. The label includes dosage instructions and an NDC code 33261-0116-60.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.